Owners
History
2022: Investment in the amount of 2.5 billion rubles from Shchelkovo Agrokhim
On August 24, 2022, it became known about the decision of the manufacturer of plant and seed protection products Shchelkovo Agrochim to enter the pharmaceutical market. According to the general director and main owner of the company, Salis Karakotov, we are talking about creating the production of full-cycle drugs - from the synthesis of active substances to the production of finished dosage forms.
As Karakotov told Kommersant, Shchelkovo Agrokhim will rely on drugs for the treatment of diseases of the nervous and cardiovascular systems. In addition, the company is exploring the possibility of producing immunomodulators - analogues of well-known drugs created using their own synthesis technologies.
The production of drugs "Shchelkovo Agrokhim" will be placed in the SEZ "Dubna" in the Moscow region. It is assumed that the production of drugs will be established at the facilities of Betaren Pharma LLC (resident of the Dubna SEZ) Alexander Burmistrov, who owns shares in the Shchelkovo Agrokhim structures. At the end of 2021, Shchelkovo Agrokhim acquired the building of the bankrupt manufacturer of printed circuit boards Svyaz Engineering KB in the Dubna SEZ for 860 million rubles, the newspaper notes.
According to Salis Karakotov, Schelkovo Agrochim plans to invest about 2.5 billion rubles in its pharmaceutical business. The launch of production is scheduled for early 2023, he said. According to Karakotov's forecasts, in two years the sales volume of a pharmaceutical enterprise will reach 5-10 billion rubles a year.
Nikolay Bespalov, Development Director of RNC Pharma, explained the desire of the fertilizer manufacturer to enter the drug market by the fact that it turned out to be practically unaffected by Western sanctions, and the demand for drugs remains stable. Nevertheless, he warned that starting production from scratch in the current environment remains a very difficult task.
The enterprise needs equipment, auxiliary substances and components, the supply of which to Russia is significantly difficult. You should not count on import substitution, since the corresponding equipment is almost not produced in the country. But even when solving these issues, the sale of drugs in a competitive environment will become a difficult task.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |